Ovarian cancer · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
IP Carboplatin and Paclitaxel Variant #01 | — | R 2 895 | 21d | ~23.5 mo | — | ~35 | ~R 101 337 PFS proxy · indirect | 1 |
IP Cisplatin and Paclitaxel Variant #02 | — | R 1 853 | 21d | — | ~65.6 mo | — | — | — |
Cisplatin and Paclitaxel (TP) Variant #01 | — | R 716 | 10d | ~16.4 mo | ~35.6 mo | ~50 | ~R 35 810 PFS proxy · indirect | 3 |
Cisplatin and Cyclophosphamide Variant #01 | — | R 679 | 21d | — | — | — | — | — |
IP Cisplatin and Cyclophosphamide Variant #01 | — | R 643 | 21d | — | — | — | — | — |
5 of 5 regimens shown